| ALLIANCE |
GREAT LAKES FORMS PARTNERSHIP WITH HIGH FORCE RESEARCH Great Lakes Fine Chemicals (GLFC) (Holywell, Wales, UK) has entered into an on-going, complimentary business partnership with High Force Research Limited (Durham, UK). Under the agreement, High Force will prepare and make available a series of aryl substituted phenylalanines and derivatives for use by the pharma and biotech companies in their new drug screening programmes. Successful candidates will be scaled up by High Force to provide gram to kilo quantities of material for drug development studies. When larger batches of product are required for clinical evaluation GLFC will scale-up the process for quantities ranging from multi-kilo to tonnes. David Rowles, Site Manager GLFC commented, 'We are delighted to enter into this agreement. It will offer our joint customers access to a range of potentially useful drug building blocks and a seamless scale-up of the process from gram to tonnes. Initially, while the drugs are in their pre-clinical and clinical Phase I and II trials, High Force and GLFC will use the GLFC assymetric hydrogenation process technology to provide the chiral phenylalanines but as the volumes increase a switch can be made to produce the phenylalanines by patented and proprietary bio-processes. This will provide a cost effective and efficient route for the supply of aryl substituted phenylalanines and their derivatives.' Bob Redfern, Managing Director, High Force Research Ltd added, 'This collaboration with Great Lakes Fine Chemicals enables us to offer an enhanced service to customers with a range of chiral products based on proprietary technology and the combined capability to supply from drug discovery to production scale.' Having invested in and developed significant technical capabilities in both biosciences (molecular biology, genetic engineering, enzymology and fermentation) and chemistry (asymmetric hydrogenation and organic synthesis) GLFC enjoys a strong patent position in these areas. The company's core expertise in chiral synthesis and unnatural amino acids represents a broad technology platform from which it develops novel, high value-added intermediates and bulk actives for the pharmaceutical industry. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |